These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 18037477

  • 1. Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
    Solá E, Vayá A, España F, Castelló R, Ramón LA, Hernández-Mijares A, Vicente V, Estellés A.
    Thromb Res; 2008; 122(3):320-7. PubMed ID: 18037477
    [Abstract] [Full Text] [Related]

  • 2. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A, Dalmau J, Falcó C, Berbel O, Castelló R, España F, Aznar J.
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [Abstract] [Full Text] [Related]

  • 3. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST, Ataç FB, Verdi H, Cetintaş S, Sahin FI, Ozbek N.
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R, España F, Vázquez C, Fuster C, Almenar SM, Aznar J, Estellés A.
    Thromb Res; 2006 May; 117(5):487-92. PubMed ID: 15907980
    [Abstract] [Full Text] [Related]

  • 5. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, España F, Cano A, Segui R, Aznar J.
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [Abstract] [Full Text] [Related]

  • 6. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, Patrassi GM, Lombardi AM, Fabris R, Girolami A.
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
    Testa R, Bonfigli AR, Sirolla C, Boemi M, Manfrini S, Mari D, Testa I, Sacchi E, Franceschi C.
    Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
    [Abstract] [Full Text] [Related]

  • 11. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P, Adarraga-Cansino MD, Fernández de la Puebla RA, Blanco-Molina A, Delgado-Lista J, Marín C, Ordovás JM, López-Miranda J, Pérez-Jiménez F.
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [Abstract] [Full Text] [Related]

  • 12. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
    Testa R, Bonfigli AR, Sirolla C, Marra M, Boemi M, Mari D, Sacchi E, Dolci A, Catalano A, Procopio A, Ceriello A.
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
    Hoffstedt J, Andersson IL, Persson L, Isaksson B, Arner P.
    Diabetologia; 2002 Apr; 45(4):584-7. PubMed ID: 12032637
    [Abstract] [Full Text] [Related]

  • 15. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB, Dupuis J, Liu C, O'Donnell CJ, Fox CS, Kathiresan S, Gabriel SB, Larson MG, Yang Q, Herbert AG, Wilson PW, Feng D, Tofler GH, Cupples LA.
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [Abstract] [Full Text] [Related]

  • 16. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
    Eroglu A, Ulu A, Cam R, Akar N.
    J BUON; 2006 May; 11(4):481-4. PubMed ID: 17309181
    [Abstract] [Full Text] [Related]

  • 17. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
    Nowakowska A.
    Ann Acad Med Stetin; 2005 May; 51(1):95-105. PubMed ID: 16496609
    [Abstract] [Full Text] [Related]

  • 18. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
    Liu SQ, Xue YM, Yang GC, He FY, Zhao XS.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
    [Abstract] [Full Text] [Related]

  • 19. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
    Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY.
    Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
    [Abstract] [Full Text] [Related]

  • 20. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
    Emingil G, Berdeli A, Gürkan A, Han Saygan B, Köse T, Atilla G.
    J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.